Finoriq research workspace
ArriVent BioPharma, Inc. (AVBP) SEC Filings & Filing Highlights
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the. Review AVBP SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.
- Company
- ArriVent BioPharma, Inc. (AVBP)
- Ticker
- AVBP
- Market Cap
- $1.3B
- Latest Price
- $28.23
- Industry
- Biotech & Pharma
ArriVent BioPharma, Inc. (AVBP) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for ArriVent BioPharma, Inc. (AVBP).
| Event | Form | Date |
|---|---|---|
| On June 18, 2026, ArriVent BioPharma, Inc. held its 2026 annual meeting of stockholders via liv...On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live aud... | 8-K5.07 | 2026-06-22 |
| ArriVent BioPharma, Inc.: Corporate updateOn May 11, 2026, ArriVent BioPharma, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) a prospectus supple... | 8-K8.01 | 2026-05-11 |
| ArriVent BioPharma Reports First Quarter 2026 Financial ResultsArriVent BioPharma Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-11 |
| ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Nove...ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC A... | 8-K7.01 | 2026-03-17 |
| ArriVent BioPharma Reports Full Year 2025 Financial ResultsArriVent BioPharma Reports Full Year 2025 Financial Results | 8-K2.02 | 2026-03-05 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.